Incretin-based therapies for obesity treatment

Aline Haas De Mello; Morgana Prá; Larissa Colonetti Cardoso; Rosiane De Bona Schraiber; Gislaine Tezza Rezin

doi:10.1016/j.metabol.2015.05.012

Incretin-based therapies for obesity treatment

Aline Haas De Mello
, Morgana Prá
, Larissa Colonetti Cardoso
, Rosiane De Bona Schraiber
, Gislaine Tezza Rezin

Research output: Contribution to journal › Review article › peer-review

28 Scopus citations

Abstract

Currently, obesity and its associated complications are considered major public health problems worldwide. Because the causes are multifactorial and complex, different treatment methods are used, which include diet and exercise, as well as the use of drugs, although they can have adverse side effects. A new target for the treatment of obesity may be the incretin system, which consists of hormones that seem to contribute to weight loss. In this sense, some studies have shown a relationship between weight loss and drugs related to incretin system, including glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. The objective of this review is to summarize the association between the incretin system and obesity treatment.

Original language	English (US)
Pages (from-to)	967-981
Number of pages	15
Journal	Metabolism: Clinical and Experimental
Volume	64
Issue number	9
DOIs	https://doi.org/10.1016/j.metabol.2015.05.012
State	Published - Sep 1 2015
Externally published	Yes

Keywords

DPP-4
GLP-1
Incretin
Obesity
Treatment

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1016/j.metabol.2015.05.012

Cite this

@article{bcf66befc9d94f948d8724c83e400024,

title = "Incretin-based therapies for obesity treatment",

abstract = "Currently, obesity and its associated complications are considered major public health problems worldwide. Because the causes are multifactorial and complex, different treatment methods are used, which include diet and exercise, as well as the use of drugs, although they can have adverse side effects. A new target for the treatment of obesity may be the incretin system, which consists of hormones that seem to contribute to weight loss. In this sense, some studies have shown a relationship between weight loss and drugs related to incretin system, including glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. The objective of this review is to summarize the association between the incretin system and obesity treatment.",

keywords = "DPP-4, GLP-1, Incretin, Obesity, Treatment",

author = "\{De Mello\}, \{Aline Haas\} and Morgana Pr{\'a} and Cardoso, \{Larissa Colonetti\} and \{De Bona Schraiber\}, Rosiane and Rezin, \{Gislaine Tezza\}",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

month = sep,

day = "1",

doi = "10.1016/j.metabol.2015.05.012",

language = "English (US)",

volume = "64",

pages = "967--981",

journal = "Metabolism: Clinical and Experimental",

issn = "0026-0495",

publisher = "W.B. Saunders",

number = "9",

}

TY - JOUR

T1 - Incretin-based therapies for obesity treatment

AU - De Mello, Aline Haas

AU - Prá, Morgana

AU - Cardoso, Larissa Colonetti

AU - De Bona Schraiber, Rosiane

AU - Rezin, Gislaine Tezza

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Currently, obesity and its associated complications are considered major public health problems worldwide. Because the causes are multifactorial and complex, different treatment methods are used, which include diet and exercise, as well as the use of drugs, although they can have adverse side effects. A new target for the treatment of obesity may be the incretin system, which consists of hormones that seem to contribute to weight loss. In this sense, some studies have shown a relationship between weight loss and drugs related to incretin system, including glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. The objective of this review is to summarize the association between the incretin system and obesity treatment.

AB - Currently, obesity and its associated complications are considered major public health problems worldwide. Because the causes are multifactorial and complex, different treatment methods are used, which include diet and exercise, as well as the use of drugs, although they can have adverse side effects. A new target for the treatment of obesity may be the incretin system, which consists of hormones that seem to contribute to weight loss. In this sense, some studies have shown a relationship between weight loss and drugs related to incretin system, including glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. The objective of this review is to summarize the association between the incretin system and obesity treatment.

KW - DPP-4

KW - GLP-1

KW - Incretin

KW - Obesity

KW - Treatment

UR - https://www.scopus.com/pages/publications/84939565602

UR - https://www.scopus.com/pages/publications/84939565602#tab=citedBy

U2 - 10.1016/j.metabol.2015.05.012

DO - 10.1016/j.metabol.2015.05.012

M3 - Review article

C2 - 26072135

AN - SCOPUS:84939565602

SN - 0026-0495

VL - 64

SP - 967

EP - 981

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

IS - 9

ER -

Incretin-based therapies for obesity treatment

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this